Compare AXGN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXGN | HRMY |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.8B |
| IPO Year | 2013 | 2020 |
| Metric | AXGN | HRMY |
|---|---|---|
| Price | $44.49 | $35.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $42.33 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 1.2M | 764.4K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 0.55 |
| Revenue | $225,208,000.00 | ★ $868,453,000.00 |
| Revenue This Year | $20.57 | $19.75 |
| Revenue Next Year | $16.68 | $12.88 |
| P/E Ratio | ★ N/A | $62.05 |
| Revenue Growth | 20.21 | ★ 21.51 |
| 52 Week Low | $10.50 | $25.52 |
| 52 Week High | $46.00 | $40.87 |
| Indicator | AXGN | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 57.98 | 63.40 |
| Support Level | $29.48 | $35.05 |
| Resistance Level | $44.83 | $35.47 |
| Average True Range (ATR) | 2.34 | 1.13 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 71.81 | 80.00 |
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.